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REPORTS OF MEDICAL ERRORS IN U.S. HOSPITALS ARE
STRONGLY INFLUENCING WHERE AMERICANS CHOOSE
TO GO FOR THEIR HEALTH CARE. According to a survey of
2000 Americans by the Kaiser Family Foundation and the
federal Agency for Healthcare Research and Quality (AHRQ),
physician and hospital error rates were ranked by respondents
at the top of their lists in deciding which hospitals or health
plans deliver quality care, while 70 percent said that medical
error rates tell them "a lot" about the quality of care a hospital
or health plan can deliver, Yahoo News reported. The survey
said that half of all American adults fear that a medical error
will affect them or their families when receiving general health
care services, and noted that consumers are not receiving
more useful measures of health care quality, Yahoo News
added. (Yahoo News, December 11, 2000)
http://dailynews. yahoo.com/h/nm/2000 1211/hl/errors 1. html
This system of using the computer to enter medical orders is
new to most of the LVH medical staff, but is not new to an
increasing number of hospitals in the country. We are teaming
from them as we start trials using Fujitsu wireless handheld
units that offer mobile access to the Phamis system.
The system will reduce errors by reducing adverse drug
interactions, allergies, wrong drug or dose due to illegibility of
handwriting or signature. It will improve use of guidelines and
clinical pathways, improve choice of cost-effective drugs, and
improve clinical research utilization. The ultimate goal is
improved quality of care. Insurers and the public will demand
this as a quality issue in the near future.
(Continued on Page 2)
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(Continued from Page 1)

Members of the LVPHO 1/S Committee and Dr. Don Levick
have been working hard on this critical project at several
different levels. Don will discuss this further at the Medical
Executive Committee meeting in February.

Everybody can be great... because anybody can serve. You
don't have to have a college degree to serve. You don't have
to make your subject and verb agree to serve ... You only need
a heart full of grace. A soul generated by love.
- Martin Luther King, Jr.

Respect
CAT Fund and the Malpractice Crisis in Pennsylvania
INCREASES IN MALPRACTICE INSURANCE PREMIUMS
COULD LEAD TO SHORTAGES IN SURGEONS,
NEUROSURGEONS, OBSTETRICIANS AND OTHER
SPECIALTIES IN THE PHILADELPHIA AREA. At Frankford
Hospital's three facilities in Northeast Philadelphia and Bucks
County, all12 active orthopedic surgeons decided to put down
their scalpels after their malpractice rates nearly doubled to
$106,000 each for 2001, reported the Philadelphia Inquirer.
Philadelphia juries have in recent months awarded a string of
record-setting, multi-million-dollar verdicts, while physicians in
counties surrounding Philadelphia are apparently being sued in
Philadelphia courts in increasing numbers because of the ease
with which plaintiff attorneys can shift trial venues. Only New
York pays out more than Pennsylvania in malpractice awards,
while Philadelphia alone paid out more in 1998 malpractice
cases than the entire state of California, according to data from
the National Association of Insurance Commissioners.
(Philadelphia Inquirer, December 31, 2000)
http://www. phillynews.corn/content/ing uirer/2000/12/31/front
paqe/MEDMAL31.ht

We will continue to highlight the goals of the medical staff
leadership on a recurring basis in Medical Staff Progress
Notes. We endeavor to respect and value each member of
the medical staff as a professional with a contribution to make.
We understand the practice pressures, monetary pressures
and time pressures that you live with daily. Your presence on
the LVH medical staff is the culmination of years of hard work,
credentialing, continuing professional education and constant
scrutiny by government and managed care, as you focus on
delivering quality medical and dental care to your patients and
the community you serve. We all need to keep this "frame of
reference" when interacting as members of the LVH team and
maintain a mutual attitude of respect. This may not always be
easy- from the Latin (notum easium).
TEAMWORK =WE CAN DO MORE TOGETHER

e~~o~
Edward M. Mullin, Jr., MD
Medical Staff President

MALPRACTICE AWARDS SURGE IN PA
http://physiciansnews.com/cover/1 01.html
Plaintiffs attorneys now seek the Philadelphia venue for their
malpractice trials due to the track record of awards there.
While the reason for this problem to be focused in
Pennsylvania (especially Philadelphia) is not clear (at least to
me), there is no question that we have a crisis brewing. We
will be discussing the malpractice surge and the CAT Fund at
the Medical Executive Committee meeting in February and,
hopefully, will have some advice on this issue that affects us
all.
Conundrum: On one hand, experts from the American College
of Surgeons and other sources advise us that solutions for
medical errors require a non-punitive systems approach to
identify the real underlying source of the error. On the other
hand, the present legal system is clearly punitive, very
expensive, and has not been successful in the past in
eliminating medical errors (otherwise the number of
malpractice cases would surely be declining by now). It is hard
to escape the conclusion that our legal system has actually
become an expensive impediment to improving the health care
delivery system in this country.

· Pro tempore
l!'.Janupry, in an effort to ~eep t~e Medical
Staff informed in a timely manner of any·
changjng developments. on the hospit(ll/medital
scene, the Medical Stafft'eadership instit'uted .
an informa.l e-.m(lil·messoge which will appear
between the editions of Mediet~l Staff
Progre~s Note.s. This new conl'munique will be
caHed·Pf!o tempore (meaning''for the time
being").· This e-ma,il upc{afe,will appe(lr aroun~
mid:-month, while Med1'col Stoff'Rrogress .
Notesqr,e published at the beginnjng of each
month. Pro tem{SOrewill also include.agenda
topics for the upcoming Me~ical Executive
Committee meeting. 'T'hls n~w communique is .
anot~er: step toward an electronic
communiCation.syste!'T', which is a goal o.f ·the
Me~icai Staff Leadership.
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News from CAPOE Central
The CAPOE project continues to make progress. Members of
the 1/S Department and I have begun to make rounds with the
Trauma team to learn their work process. This will help in the
design and implementation of CAPOE. The Design Team has
also begun to meet. This is a group of physicians, nurses and
support staff who will provide input and feedback regarding the
screen design and user interface of the CAPOE system. The
members have been provided with a test version of the
system, and will be dealing with specific design issues over the
next several weeks. I am encouraged by everyone's interest
and enthusiasm, especially given that the meetings begin at
6:30a.m. The members of the Design Team will also serve as
resources for the Medical Staff. If you would like a demo of the
system, please contact me or any member of the Design Team
listed below.
Members ofthe Design Team
•
Don Belmont, MD
•
David Caccese, MD
•
Dave Carney, MD
•
Michael Ehrig, MD
•
Larry Glazerman, MD
•
Rick MacKenzie, MD
•
Rovinder Sandhu, MD
•
Brian Stella, MD
•
Jeff Faidley, MD, Internal Medicine Resident
•
William Bromberg, MD, Chief Surgical Resident
•
Betsy Davies, PA
•
Daniele Shollenberger, CRNP
The PHO 1/S Committee met on January 15, 2001. The main
thrust of the group will be to investigate the various officebased prescription writing systems (i.e., iScribe, AIIScripts,
PHAMIS/IDX PrescriptionPad). The group will attempt to
identify a computerized prescription writing system that is most
compatible with the majority of office practice management
systems. We then hope to negotiate the best deal for our
membership. We strongly encourage input from the medical
staff. Please let me know your experiences with any of these
systems, or if you would like to participate in this process.
Don Levick, MD, MBA
Chair, LVPHO 1/S Committee
Phone: (484) 884-4593

Urologic Cancer Second Opinion
Service
In an effort to provide a needed service for patients in the
Lehigh Valley area and attract out-of-area patients, the
Urologic Cancer Second Opinion Service was developed. This
service, which opened at LVH-Muhlenberg in July, 2000, is the
first of its kind in the region and features four LVHHN
specialists --Victor M. Aviles, MD, medical oncologist; Steven
J. Perch, MD, radiation oncologist; Melvin L. Steinbock, MD,
urologist, and Joseph G. Trapasso, MD, the region's only
fellowship-trained urologic oncologist.
"People diagnosed with prostate, bladder, kidney or testicular
cancer often have questions about side effects, risks and the
best treatment," said Gregory R. Harper, MD, physician-inchief of cancer services. "Our team evaluates patients in one
visit and gives them a personal and written explanation of the
recommendation, helping relieve some of their fear, confusion,
and anxiety.
According to Dr. Harper, the service works closely with
referring physicians by offering their patients convenient local
access to second opinions. For the first time, area residents
can get a second opinion for urologic cancer without having to
travel to Philadelphia or New York. Patients are expected from
as far north as Binghamton, NY, as far east as north-central
New Jersey, as far west as Lancaster, and as far south as
Montgomery, Bucks and Chester counties.
The new service is a component of LVHHN Cancer Services
that offers the latest diagnostic and treatment methods,
including the area's most experienced laparoscopic surgery
and the region's most experienced radioactive seed implants
program. Patients are also offered information about a variety
of urologic clinical trials and national research studies for
treatment and prevention that are available through Cancer
Services.
For more information regarding the Urologic Cancer Second
Opinion Service, please call (610) 402-CARE (2273).
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E-mail Surrogates
With e-mail being used more and more frequently to
communicate information to the Medical Staff, all members of
the Medical Staff are encouraged to read their e-mail regularly
or to designate a staff member to be your appointed
"surrogate" who can read and print out your e-mail messages
for you on a daily basis.
To make life easier for you, following are instructions for
setting up a surrogate:

Step 1 • Instructions for the User
To define a surrogate, you must specify the user(s) who you
wish to name as surrogate and select the features the
surrogate will be authorized to access.

1. From the main menu, choose Tools, Configure, and TAO

2.

Use the Search box or scroll bar to locate the MaiiiD of
the person for whom you wish to act as surrogate.
Double-click the desired Mail ID. It appears in the
Surrogate For box. Click OK to confirm your selection.
The TAO user whose MaiiiD you specify must have
designated you as their surrogate. If not, a message
displays notifying you that you have not been defined as a
surrogate. Once TAO recognizes you as a surrogate, the
main TAO window displays. The Folder list and icon bar
reflect the features that you can access.

3. When you have completed your surrogate a.ctivities and
are ready to exit Surrogate mode, choose F1le, End
Surrogate Mode.

If you or the person who you wish to become your
surrogate is not currently on the hospital's e-mail system,
please contact Pat Skrovanek in Physician Relations at

(610) 402·9190.

Profile Option
2. Click the Surrogates tab

Infection Control Notices

3.

PreOp Showering

In the Current Surrogates box, either type in the MaiiiD of
the user you want to name as surrogate or click the Select
button to select a MaiiiD from the MaiiiD Directory. To
delete a MaiiiD, select the MaiiiD and press the Delete
Key. When you remove a surrogate from the list, that user
no longer has permission to act as your surrogate. To
designate all users on your system as your surrogates,
without references to class or department, enter
*EVERYONE in the Edit box. To specify all members of
your department as your surrogates, enter
*DEPARTMENT in the Edit box.

4. In the Surrogate Abilities box, check the surrogate
functions you want to grant to your surrogate(s). You may
update a surrogate at any time to reassign powers. Select
the desired MaiiiD in the Current Surrogates box and then
click the checkbox next to the function you want your
surrogate to perform. Repeat this step for each MaiiiD to
receive surrogate powers.

Step 2 • Instructions for the Surrogate
Having access to Surrogate mode does not mean that you can
act as someone's surrogate. Someone must have named you
as surrogate and granted you powers in order for you to sign
on to their account.

1. To enter Surrogate mode, choose File, Surrogate Mode.
The Surrogate For dialog displays.

This is a reminder that chlorhexidine (Hibiclens) is the
preferred antiseptic agent for pre-operative showering.
Surgeons and their staff are encouraged to ~ecom'!len~ the
use of Hibiclens as the preferred pre-operative ant1sept1c agent
when instructing patients to shower/bathe prior to surgery.
Hibiclens is available at all three Health Spectrum Pharmacies
(Cedar Crest & 1-78, 17th & Chew and LVH-M) at a nominal
cost to the patient.

Influenza
Influenza A and B are both circulating in the community. There
is still time to vaccinate patients and their caregivers before the
impact of the flu becomes severe. Delays in the manufacturing
of the vaccine have subsided and full supplies are available.
Aggressive measures to catch up on vaccinating patients at
risk are needed to curb the effects of this potentially
devastating virus.
If you have any questions, please contact the Infection Control
Department at (610) 402-0680.
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News from the Health Information
Management Department
Document Imaging Update

Cedar Crest &1-78, 17fh &Chew and Westgate (Behavioral
Health Science Center) - The Health Information Management
(HIM) Department is currently in the implementation phase for
the document imaging (Pathways Image Manager) upgrade.
System upgrade will provide enhanced functionality and better
access to patient records. Because of an entirely new look
and feel to the system screens, plus increased functionality, all
physicians must receive additional training. The good news,
however, is that the training will require about the same
amount of time as the original training ... approximately 15-20
minutes. Targeted implementation date for Cedar Crest &
1-78, 17th &Chew, and Westgate is scheduled for April, 2001.
LVH-M- Following completion of the LVH upgrade,
implementation will begin at the LVH-M campus beginning in
May, 2001. Targeted implementation is as follows:

May, 2001 - Start scanning medical records into imaging
system
June, 2001 - Physician Training
-Transition from paper to computerized
access/record completion
Please stay tuned for updates regarding implementation
progress.
Death Certificate Completion
Effective February 1, the HIM Department will no longer have
the assistance of a Decedent Affairs Consultant to assist with
death certificate completion. The current process will remain
the same with physicians being asked to complete one death
certificate (including the cause of death) and signature and one
signed to have the cause of death typed and legible. You are
encouraged to complete the death certificate at the time the
patient is pronounced and cause of death is determined.
Death certificates not completed by the time the patient's chart
has been removed from the office will be handled through the
HIM Department at Cedar Crest & 1-78. Since this process is
being handled in-house, death certificates will no longer be
delivered to physician offices for signature/completion. The
HIM staff will call to remind you of incomplete death
certificates.
Since the death certificate is not part of the patient's medical
record, you are requested to include the (1) circumstances of
patient's death, (2) cause of death, and (3) whether an autopsy
was performed in the final progress note in the medical record.

Advance Directive, Living Will, Durable Power of Attorney
The Patient Self-Determination Act mandates that all hospitals
and other specified Medicare or Medicaid-funded health care
facilities provide a mechanism for advising patients of their
legal rights and options for refusing or accepting treatment if
they are, or become, incapacitated. This can be done in the
form of advance directives, living wills, durable power of
attorney, do not resuscitate orders, right to die, etc.
Although the Patient Care Services staff discuss Advance
Directives with patients when they are admitted for services,
one of the recommendations made by the Joint Commission
during the December, 2000 survey was that physicians initiate
this process when patients are seen in their office prior to
receiving services at the hospital. By beginning this process
when they are seen in the physician's office, patients have an
opportunity to ask questions of the physician and prepare to
have the documentation available at the time services are
provided in the hospital.
Suspension Process
Since the medical record completion process is electronic at
the Cedar Crest & 1-78, 17th & Chew, and Westgate
(Behavioral Health Science Center) sites, physicians are again
reminded to call the HIM Department at (610) 402-8240 once
records are completed after suspension of privileges has been
initiated. This will enable the HIM Department to notify the
appropriate departments to resume admission privileges.
Currently, there is no automated way for the system to notify
HIM when the charts have been completed for physicians who
have had privileges suspended.
If you have any questions regarding these issues, please
contact Zelda Greene, Director, Health Information
Management, at (610) 402-8330.

.·coding Tip of the Month
~~thma with Acute Exac~rbatipn - A chronic,

stable ~onditibn is not necessarily an indication
for admission to· the:hospital·unless the·
p~tient just received this diagnosis for the
first time or the disease .process has
deter(orated significantly. In the case of
as{~ma,please pe ·sure to d,.ocument if the
patient, has acute.exacerbation,of asthma or
chronic obstructive aSthma with acute
exacerbation.
,,
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Radiology News
Imaging to Screen for Renal Artery Stenosis
There are several imaging modalities available as screening
tools to be used prior to more invasive angiography
procedures in the evaluation of renal artery stenosis.
Magnetic resonance arteriography (MRA) with Gadoliniun
enhanced sequences provides arteriogram-like images of the
renal arteries. Sensitivities and specificities of greater than
90% are frequently reported in the literature. Advantages of
MRA include the ability to obtain arteriogram-like images
without the risk of nephrotoxic contrast material and the ability
to evaluate the abdominal aorta prior to percutaneous or
surgical intervention including the origin of the celiac artery (a
potential source of inflow for surgical reconstruction). MRA
can also provide functional information (i.e. delayed
nephrogram) which may help determine the significance of a
stenosis. Limitations of MRA include its frequent restriction to
detection of stenoses of the main renal arteries as the
divisional, segmental and small accessory arteries may be
difficult to image reliably, visualize or grade accurately. Patient
motion, metal/calcium artifacts and flow artifacts may degrade
the images. Contraindications to MRA include the presence of
a pacemaker or intraoccular metallic foreign body.
Another technique that provides arteriogram-like images of the
renal arteries is computed tomography arteriography (CTA).
Imaging is performed by continuous acquisition of a volume of
data as the patient is moved through the scanner during rapid
intravenous injection of a large volume of iodinated contrast
material, approximately 150 mi. Several studies have reported
sensitivities and specificities of >I= 90% for detection of main
renal artery stenosis. As with MRA, the entire abdominal aorta
can be imaged allowing evaluation of concomitant aortic and
visceral vessel disease. Unlike MRA, in which the signal from
the background tissues is suppressed or absent, CTA retains
anatomic information about all of the abdominal contents and
the degree of vascular calcification is accurately depicted. The
chief disadvantage of CTA is its absolute requirement for
iodinated contrast material. The technique is therefore not
suitable for patients with renal insufficiency or contrast material
allergies. Other limitations include inconsistent visualization of
small or accessory arteries and distal branches of the main
renal artery. Heavily calcified plaque may obscure the vessel
lumen, making stenoses difficult to grade. Patient motion or
respiration during the examination creates artifacts that
degrade image quality.
Conventional ultrasound (US} may suggest renal artery
stenosis when a small kidney is identified, but Doppler US is
required for evaluation of renal artery flow. The diagnosis of
renal artery stenosis is based upon the Doppler estimation of
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blood flow rather than imaging of the actual lesion. The site of
the lesion can be localized by a sudden increase in the peak
systolic velocity within the vessel. However, determination of
the peak systolic velocity alone is a poor indicator of significant
renal artery stenosis and, as a result, other criteria have been
proposed for the diagnosis of a hemodynamically significant
lesion such as a ratio of the peak systolic velocity in the renal
artery to that in the aorta of >I= 3.5, or delay in the measured
systolic acceleration in segmental renal arteries. Doppler US
has reported sensitivity of 95% and specificity of 90% for
detection of renal artery stenosis >/= 60%. However,
complete Doppler US interrogation may not be possible in as
many as 15% of patients. Large body habitus, tortuous arterial
anatomy, severe renal artery stenosis or occlusion, and
multiple renal arteries seriously limit the usefulness of the
study. Also, these studies are extremely technologist operator
dependent and may be very time-consuming requiring up to
two hours in a difficult patient and may end in an inadequate
study requiring MRA for evaluation.
Enalapril-stimulated nuclear studies image renal function and,
indirectly renal artery flow. Renal artery stenosis is implied by
decreased and delayed renal uptake of the
radiopharmaceutical after the administration of Enalapril since
Enalapril reduces the glomerular filtration pressure distal to the
stenosis. In properly selected patients, the sensitivity of this
test is approximately 90% and the specificity is approximately
95%. Although false-positive studies are unusual, falsenegative results can occur in patients with bilateral disease,
stenosis of one of multiple renal arteries, dehydration and
azotemia.
At LVH, the current recommendation is to utilize MRA as the
screening procedure of choice in the detection of renal artery
stenosis, although CTA or a nuclear study is a viable
alternative, especially in patients who cannot remain still for
the time required for an MRA study.
If you have any questions, please contact Darryn Shaff, MD,
Division of Diagnostic Radiology, at (610) 402-8088.

The members of the Division of Hema:tology-Medical.
Onco1ogy·have agreed to incorpor!lte, all patients from
the 11~mdtology oncology clinic;into their private o,ffic:e
practiees b¢ginning in February.
The prifleipal sour.ces of referrals are medical and
surgical clinic, inpatient tnedical and surgical.service'
patients, and occasionally, other ':"edical staff or the
stote hospifol. .
·
· ·
A l~tter to the Medico! Stoff communi~oting this chonge
. on. d'the, new referral process is ahac~.ed on Page 15.
'

'
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New Weight Management Program
The Helwig Diabetes Center Weight Management Program is
open and taking referrals. The program is designed to assist
the patient who needs to lose a minimum of 60 pounds (BMI
over 30) and has at least one co-morbidity. Individual goals
will be determined for each patient and the program will be
guided by the NIH algorithm for obesity. Keith R. Doram, MD,
Chief, Division of Generallntemal Medicine, and Larry N.
Merkle, MD, Chief, Division of Endocrinology-Metabolism,
provide physician leadership for the program and have been
instrumental in its development. Maintaining open
communication with the referring physician is an important part
of using the NIH weight management algorithm. The staff of
the Helwig Diabetes Center works with the referring physician
during the program and as evaluations for education
medication and surgical options become relevant. '
The program includes two segments. The initial nutrition
counseling includes an individual assessment, diet evaluation
and meal planning with the patient. The second segment of
the program is six months in length and includes four weeks of
nutrition education, four weeks of supervised exercise
(Exercise for Life Programs), and four months of supervised
follow-up. All patients must be willing and able to participate in
eac~ activity. The group exercise classes are instructed by
certified fitness specialists and are sensitive to the needs of
the obese individual. While the classes stress flexibility,
strength training and conditioning, individuals participate
according to tolerance at least three times a week. Nutrition
education stresses behavioral change and healthy food
selection including guidelines for shopping and restaurant
meals. Supervised follow-up encourages the patient to
maintain their program and allow the health educators to
continue education and support.
This program offers a unique, comprehensive approach to the
treatment of the obese patient. For more information, please
contact the Helwig Diabetes Center at (610) 402-5000.

CHF Patients Sought for Clinical Trial
Patients with Class Ill or IV congestive heart failure may qualify
for the COMPANION clinical trial, which is testing the
effectiveness of bi-ventricular cardiac synchronization in
improving patients' survival rate, quality of life and ability to
exercise, and decrease their length and frequency of
hos~italiz.ation. The study is sponsored by the Guidant Corp.
and 1s bemg conducted at LVH by Luis Constantin, MD, James
Sandberg, MD, and Steven Zelenkofske, DO, members of the
Division of Cardiology.

COMPANION is a randomized study in which participants will
be placed in one of the following groups:
•!• They will receive the CONTAK TR bi-ventricular
pacemaker and optimal pharmacologic therapy; or
•:• They will receive the combination CONTAK CD
pacemaker/defibrillator and optimal pharmacologic
therapy; or
•!• They will receive only optimal pharmacologic therapy.

Please consider referring a patient for possible enrollment in
this trial, based on the following inclusion and exclusion
criteria:
Inclusion Criteria
Moderate or severe symptomatic heart failure for at
least 6 months at the time of enrollment
2.
Left or right bundle branch block with QRS > 120 ms
3.
Left ventricular ejection fraction< 35% 4.
Older than 18 years
-

1.

Exclusion Criteria
1.
Meet the general indications for an implantable
cardioverter defibrillator and/or pacemaker
2.
Myocardial infarction within 60 days of randomization
3.
Life expectancy < 6 months due to any other medical
condition
To refer a patient to the COMPANION study, or to learn more
about it, please call Patti Frey or Cherie Tyler, study
coordinators for The Heart Care Group, at (610) 778-3667.

More Clinical Trials
Ne~roscienc~s .and ~ain Research is currently recruiting
pat1ents for chmcal tnals in the following areas:

•!• Adjuvant Cancer Pain - add-on therapy for patients who
are currently on opioids.
•:• Diabetic Neuropathy - patients who are experiencing
polyneuropathy secondary to diabetes.
•!• Constipation secondary to Opioid use - severe
constipation, less than three bowel movements per week.
May be using laxatives and other stool softeners.
There are several inclusion and exclusion criteria for each
study..For mo.re information on any of the studies or if you
would hke to d1scuss a potential candidate, please contact
Maryjane Cerrone, RN, Clinical Research Specialist at (610)
402-9008.
,
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Cancer Survivorship Study

Congratulations!

Some of your patients who are cancer survivors may ask you
about a study in which they have been asked or will be asked
to participate. The study, funded by the National Cancer
Institute, and administered by the Center for Health Policy
Research at Penn State University, is a collaboration of Lehigh
Valley Hospital, Hershey Medical Center, Geisinger, and Johns
Hopkins Oncology Center.

John D. Karabasz, DMD, Chief, Division of Prosthodontics,
was awarded the Leonard Pool Prize for Outstanding
Contribution to Health Care in the Lehigh Valley for his efforts
in supporting optimal fluoridation of the Allentown water
supply. Dr. Karabasz has been the driving force behind the
effort to organize community support to improve the dental
health of the citizens of Allentown. He has dedicated many
hours to raising community awareness to the benefits of
fluoride through his work with the Allentown-based Citizens for
Children's Dental Health activities.

Patients identified by the tumor registries at the participating
institutions who meet eligibility requirements are being asked if
they would be willing to participate in a survey study about
people who have had cancer. The study is designed to
provide information about how their experience with cancer
has affected them, especially employment and economic
aspects of their life. The study has been reviewed and
approved by the IRBs at each institution, and the Penn State
University.

William J. Smolinski, DO, Division of Cardiology, was
recently elected to Fellowship in the American College of
Physicians - American Society of Internal Medicine.

One of the stipulations of each IRB was that contacts with
patients would be made by people from their "home" institution.
Members of the cancer program at LVH are currently
undertaking follow-up inquiries, and some of your patients may
ask you about the study.

Medical Grand Rounds

Responses are, of course, completely confidential, and will not
be traceable to an individual respondent. The survivors have
multiple opportunities to decline to participate, either by
notifying by return postcard, declining when contacted by
phone, or declining to continue during the questionnaire if they
previously agreed to participate.
If you have any questions regarding this study, please contact
Gregory R. Harper, MD, PhD, Physician in Chief, Cancer
Services, at (610} 402-0512.

. WOtJND ·~RE SERVICES.
are still 'ovailoble to you and yot:Jr patients at the
Wound Healing Program LVH ...M

at

(formerly the Wound Care Center).
Hours of Oper~tion:
Mondoy through •Friday
. 8:a.m. to 4:30 p.m.
To.mC!ke an appointmen.t for your pc;~tients,
plecise coif the Wound Healing Program ·
at (484) 884-2989.
fo~ additiortaHnfo,.matfbn, plea~e call
Ginger A.Holko, RN, BSI'\l; Director, .
at (484) 884.. 2.989.

'i.

Upcoming Seminars, Conferences and
Meetings

Medical Grand Rounds are held every Tuesday beginning at
noon in the Auditorium of Lehigh Valley Hospital, Cedar Crest
&1-78, and via videoconference in the First Floor Conference
Room at Lehigh Valley Hospital-Muhlenberg.
Topics to be discussed in February will include:

•!• February 6- New Techniques in Electrophysiology
•:• February 13 - Breast and Prostate Cancer Chemo
Prevention Trials
•!• February 20- Under and Over Eaters-- Young and Old:
A Panel Discussion
•!• February 27 - Gastroesophageal Reflux and Esophageal
Cancer
For more information, contact Diane Biernacki in the
Deparmtent of Medicine at (610} 402-5200.

Department of Pediatrics Conference
"Update on Pediatric HIV Infection: Trends, Tests and
Therapies" will be presented on Tuesday, February 6,
beginning at 8 a.m., in the hospital's Auditorium at Cedar Crest
& 1-78.
For more information, please contact Kelli Ripperger in the

Department of Pediatrics at (610) 402-2540.
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Papers, Publications and Presentations
"My Bride," an oil painting by John A. Altobelli, MD, Division
of Plastic Surgery, was featured on the cover of the
November/December 2000 issue of the Aesthetic Surgery
Journal.
George A. Arangio, MD, Division of Orthopedic Surgery,
Section of Ortho Trauma, completed the visiting clinician
program in Foot and Ankle Surgery at the Rizzoli Orthopedic
Institute in Bologna, Italy. While he was there, Dr. Arangio
presented clinical applications of a mathematical model of the
foot and ankle to the Department of Orthopedics and
·
Biomechanics.
Victor M. Aviles, MD, Associate Chief, Division of
Hematology-Medical Oncology, co-authored two articles. The
first article, "Tall Cell Papillary Carcinoma of the Thyroid:
Metastatic to the Pancreas," was published in the February,
2000 issue of Thyroid. The second article, "Pilot Study of
Organ Preservation Multimodality Therapy for Locally
Advanced Resectable Oropharyngeal Carcinoma," was
published in the October, 2000 issue of the American Journal
of Clinical Oncology. In addition, Dr. Aviles co-authored
"Care of the Cancer Patient with Neutropenia and
Thrombocytopenia," a chapter which appears in The Intensive
Care Unit Manual, which was published last year by W. B.
Saunders.
Mark A. Gittleman, MD, Division of General Surgery, recently
had an editorial published in the October, 2000 issue of The
American Journal of Surgery. The editorial was titled "The
Surgeon and Breast Ultrasonography Procedures."
lndru T. Khubchandani, MD, Division of Colon and Rectal
Surgery, was a visiting professor at Jaslok Hospital, Bombay,
India, from January 6-14. He demonstrated endoscopic
procedures and helped to organize the Association of Colon
and Rectal Surgeons of India with the Executive Committee of
the Group.
Robert X. Murphy, Jr., MD, Division of Plastic Surgery/Hand
Surgery, Section of Bum; K. Lesley Birmingham, MD, former
Plastic Surgery resident; Walter J. Okunski, MD, Division of
Plastic Surgery/Hand Surgery, Section of Bum; and Thomas
E. Wasser, PhD, Department of Health Studies, co-authored
an article, "Influence of Restraining Devices on Patterns of
Pediatric Facial Trauma in Motor Vehicle Collisions," which
was published in the January, 2001 issue of the Journal of
Plastic and Reconstructive Surgery.
Four members of the Division of Colon and Rectal Surgery -Robert D. Riether, MD, John J. Stasik, MD, Chief, Lester
Rosen, MD, and lndru T. Khubchandani, MD --co-authored
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a paper with former Colon and Rectal Surgery resident,
Khawaja Azimuddin, MD. The paper, "Transanal Endoscopic
Microsurgery for Excision of Rectal Lesions: Technique and
Initial Results," was published in the December, 2000 issue of
Surgical Laparoscopy, Endoscopy &Percutaneous
Techniques.
Randolph Wojcik, MD, General Surgery resident, presented
his paper, "Pre-injury Warfarini Does Not Impact Outcome in
Trauma Patients," at the Eastern Association for the Surgery of
Trauma Annual Meeting in Orlando, Fla., on January 11. Coauthors of the paper are Mark D. Cipolle, MD, PhD, Chief,
Section of Trauma Research, Elizabeth Seislove, RN, and
Thomas E. Wasser, PhD, Department of Health Studies.

Who's New
The Who's New section of Medical Staff Progress Notes
contains an update of new appointments, address changes,
resignations, etc. Please remember to update your directory
and rolodexes with this information. In addition, the Medical
Staff Directory is now available on the e-mail Bulletin Board -Directories. Updates will be made to the Medical Staff
Directory in e-mail at the beginning of each month.
Medical Staff
New Appointments
Richard E. Brannan, DO
Primary Care Associates in the LV, PC
1150 S. Cedar Crest Blvd., Suite 101
Allentown, PA 18103-7900
(610) 776-1603 + Fax: (610) 776-6344
Department of Medicine
Division of General Internal Medicine
Site of Privileges - LVH & LVH-M
Provisional Active
Rene A. Chapados, MD
CHOP-Pediatric Critical Care Medicine
Children's Hospital of Philadelphia
324 S. 34th Street
Dept., Anesthesiology & Critical Care Medicine
Philadelphia, PA 19104-4399
(215) 590-5505 + Fax: (215) 590-4327
Department of Pediatrics
Division of Hospital Based Pediatrics
Section of Critical Care Medicine
Site of Privileges - LVH & LVH-M
Provisional Limited Duty

(Continued on Page 10)

Number2
Robert J. Corba, DO
Allentown Anesthesia Associates Inc
The Center for Pain Management
1240 S. Cedar Crest Blvd., Suite 307
Allentown, PA 18103-6218
(610) 402-1756 • Fax: (610) 402-1747
Department of Anesthesiology
Division of Pain Management
Site of Privileges - LVH & LVH-M
Provisional Active
Daniela H. Davis, MD
CHOP-Pediatric Critical Care Medicine
Children's Hospital of Philadelphia
324 S. 34th Street
Dept., Anesthesiology & Critical Care Medicine
Philadelphia, PA 19104-4399
(215) 590-5505 • Fax: (215) 590-4327
Department of Pediatrics
Division of Hospital Based Pediatrics
Section of Critical Care Medicine
Site of Privileges - LVH & LVH-M
Provisional Limited Duty
Marguerite V. DeWitt, MD
Forensic Pathology Associates Inc
Lehigh Valley Hospital
Cedar Crest & 1-78, P.O. Box 689
Allentown, PA 18105-1556
(610) 402-8144 • Fax: (610) 402-5637
Department of Pathology
Division of Anatomic Pathology
Section of Forensic Pathology
Site of Privileges - LVH & LVH-M
Provisional Active
Cromwell C. Estrada, DO
19th Street Family Health Care, PC
19th Street Health Center
1901 Hamilton Street, Suite 2
Allentown, PA 18104-6413
(610) 437-7181 • Fax: (610) 435-0597
Department of Family Practice
Site of Privileges - LVH & LVH-M
Provisional Active
HongJin, MD
Children's Heart Center of Northeastern PA
Allentown Medical Center
401 N. 17th Street, Suite 309
Allentown, PA 18104-5050
(610) 437-6687 • Fax: (610) 437-5232
Department of Pediatrics
Division of Pediatric Subspecialties
Section of Cardiology
Site of Privileges - LVH & LVH-M
Provisional Active

Eva R. Michael, MD
(Solo Practice)
1566 Eighth Avenue
Bethlehem, PA 18018-1829
(610) 691-8502
Department of Family Practice
Site of Privileges - LVH & LVH-M
Provisional Active
Joel D. Portnoy, MD
CHOP-Pediatric Critical Care Medicine
Children's Hospital of Philadelphia
324 S. 34th Street
Dept., Anesthesiology & Critical Care Medicine
Philadelphia, PA 19104-4399
(215) 590-5505 • Fax: (215) 590-4327
Department of Pediatrics
Division of Hospital Based Pediatrics
Section of Critical Care Medicine
Site of Privileges - LVH & LVH-M
Provisional Limited Duty
Steven E. Schultz, MD
CHOP-Pediatric Critical Care Medicine
Children's Hospital of Philadelphia
324 S. 34th Street
Dept., Anesthesiology & Critical Care Medicine
Philadelphia, PA 19104-4399
(215) 590-5505 • Fax: (215) 590-4327
Department of Pediatrics
Division of Hospital Based Pediatrics
Section of Critical Care Medicine
Site of Privileges - LVH & LVH-M
Provisional Limited Duty
Kimberly R. Sheets, MD
Riverside Medical Associates
Riverside Professional Center
5649 Wynnewood Drive, Suite 203
Laurys Station, PA 18059-1124
(610) 261-1123 • Fax: (610) 262-1739
Department of Family Practice
Site of Privileges - LVH & LVH-M
Provisional Affiliate
Eric P. Wilson, MD
Peripheral Vascular Surgeons, PC
1259 S. Cedar Crest Blvd., Suite 301
Allentown, PA 18103-6260
(610) 439-0372 • Fax: (610) 439-8807
Department of Surgery
Division of Vascular Surgery
Site of Privileges - LVH & LVH-M
Provisional Active
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Athena F. Zuppa, MD
CHOP-Pediatric Critical Care Medicine
Children's Hospital of Philadelphia
324 S. 34111 Street
Dept., Anesthesiology & Critical Care Medicine
Philadelphia, PA 19104-4399
(215) 590-5505 • Fax: (215) 590-4327
Department of Pediatrics
Division of Hospital Based Pediatrics
Section of Critical Care Medicine
Site of Privileges - LVH & LVH-M
Provisional Limited Duty

Appointments to Medical Staff Leadership Positions
George A. Aranglo, MD
Department of Surgery
Division of Orthopedic Surgery
Section of Ortho Trauma
Position: Chief, Section of Foot and Ankle Surgery
Ravindra Bollu, MD
Department of Medicine
Division of Nephrology
Position: Medical Director, Transplant Nephrology
Keith R. Doram, MD
Department of Medicine
Division of General Internal Medicine/Geriatrics
Position: Vice Chair for Clinical Affairs, Department of Medicine
William F.lobst, MD
Department of Medicine
Division of Rheumatology
Position: Vice Chair for Education, Department of Medicine
Michael J. Pistoria, DO
Department of Medicine
Division of General Internal Medicine
Position: Assistant Program Director, Internal Medicine Residency
Program

Status Changes
Suzette V. Barreto, MD
Department of Medicine
Division of General Internal Medicine
From: Provisional Active
To: Associate
Site of Privileges - LVH & LVH-M
Theodore W. Eastland, MD
Department of Family Practice
From: Active
To: Honorary

Marla L. Jones, MD
Department of Medicine
Division of General Internal Medicine
From: Provisional Active
To: Associate
Site of Privileges - LVH & LVH-M
Charles F. Kelley, Jr., MD
Department of Pediatrics
Division of General Pediatrics
From: Active
To: Honorary
Neal Kramer, DPM
Department of Surgery
Division of Orthopedic Surgery
Section of Foot and Ankle Surgery
From: Associate
To: Provisional Active
Site of Privileges - LVH-M
Hugh J. O'Donnell, Jr., DDS
Department of Dentistry
Division of Pediatric Dentistry
From: Active
To: Associate
Site of Privileges - LVH & LVH-M
Geraldo A. Saavedra, MD
Department of Medicine
Division of Endocrinology-Metabolism
From: Provisional Active
To: Affiliate
Site of Privileges - LVH & LVH-M
Jeffrey W. Thompson, MD
Department of Family Practice
Division of Occupational Medicine
From: Active
To: Affiliate
Site of Privileges - LVH & LVH-M
John S. Wheeler, MD
Department of Pediatrics
Division of General Pediatrics
From: Affiliate
To: Honorary
Douglas C. Wiseman, DO
Department of Medicine
Division of Allergy
From: Associate
To: Affiliate
Site of Privileges - LVH & LVH-M
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Two-Year Leave of Absence

Practice Changes

Stephen K. Klasko, MD
Department of Obstetrics and Gynecology
Division of Primary Obstetrics and Gynecology

Joseph J. Grassi, MD
(No longer with Orthopaedic Associates of Bethlehem)
Orthopedic Associates of the Greater Lehigh Valley
3735 Easton Nazareth Highway
Suite 101
Easton, PA 18045-8338

Robert P. Oristagllo, DO
Department of Medicine
Division of General Internal Medicine

(610) 252-1600
Fax: (610) 250-9257

Deborah L. Villeneuve, MD
Department of Obstetrics and Gynecology
Division of Primary Obstetrics and Gynecology

Additional One-Year Leave of Absence
Karen M. Matz, MD
Department of Obstetrics and Gynecology
Division of Primary Obstetrics and Gynecology

Address Changes
Wayne E. Dubov, MD
Good Shepherd Physician Group
Good Shepherd Outpatient-Cedar Crest
1243 S. Cedar Crest Blvd.
Allentown, PA 18103-7982

(610) 776-3278
Fax: (610) 402-5942
Manny lyer, MD
201 Drift Court
Bethlehem, PA 18020

(610) 865-5500
Fax: (610) 861-3065
Northampton Medical Associates
•:• Michael S. Hortner, MD
•:• Lisa H. Medina, MD
•:• Daniel M. Spatz, Jr., MD
6028 East 21st Street
Suite 400
Northampton, PA 18067-1247

(610) 262-1519
Fax: (610) 262-7125

Address Correction
Jonathan H. Munves, MD
800 Ostrum Street
Suite 102
Bethlehem, PA 18015-1009

Gerald M. Zupruk, MD
(No longer with Lehigh Valley Neurosurgery)
Eastern Pennsylvania Neurosurgical Associates
303 W. Broad Street
Bethlehem, PA 18018-5526

(61 0) 882-4460
Fax: (610) 691-8384

Resignations
Joseph L. Antonowicz, MD
Department of Psychiatry
Section of Consultation-Liaison Psychiatry
Darren G. Brenner, DMD
Department of Dentistry
Division of General Dentistry
Thomas L. Carter, Jr., MD
Department of Surgery
Division of Cardio-Thoracic Surgery
H. Thompson Dale, MD
Department of Medicine
Division of Cardiology
Constance R. DIAngelo, MD
Department of Pathology
Division of Anatomic Pathology
Section of Forensic Pathology
Beth A. Folio, MD
Department of Obstetrics and Gynecology
Division of Primary Obstetrics and Gynecology
Samuel R. Giamber, MD
Department of Medicine
Division of Cardiology
Donald P. Goldsmith, MD
Department of Pediatrics
Division of Pediatric Subspecialties
Section of Rheumatology
Charles Honeckman, DO
Department of Pathology
Division of Anatomic Pathology

Number2
Lila N. Inouye, MD
Department of Pathology
Division of Anatomic Pathology
Anna Niewiarowska, MD
Department of Medicine
Division of Hematology-Medical Oncology
Janet L. Osborne, MD
Department of Obstetrics and Gynecology
Division of Gynecology
Section of Gynecologic Oncology
Rajen P. Oza, MD
Department of Medicine
Division of Hematology-Medical Oncology
Susan K. Pedott, DMD
Department of Dentistry
Division of Endodontics
Peter R. Puleo, MD
Department of Medicine
Division of Cardiology
Steven J. Svabek, DO
Department of Surgery
Division of Orthopedic Surgery
Richard C. Wilson, MD
Department of Medicine
Division of Car~iology
Yelena M. Yerrnak, MD
Department of Psychiatry
Section of Consultation-Liaison Psychiatry

Allied Health Professionals
Appointments
Patti Sue Connolly, PA
Physician Extender
Physician Assistant- PA
(Orthopaedic Associates of Allentown- Gregor M. Hawk, MD)
Site of Privileges - LVH & LVH-M
Ethyl C. Davis, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc - Alphonse A. Maffeo, MD)
Site of Privileges - LVH & LVH-M
Natalie L. Fahs, PA·C
Physician Extender
Physician Assistant- PA-C
(Cedar Crest ENT Associates, PC- Theodore H. Gaylor, MD)
Site of Privileges - LVH & LVH-M
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Archie W. Hartzell, PA
Physician Extender
Physician Assistant- PA
(Orthopaedic Associates of Bethlehem, Inc- Thomas S. Sauer, MD)
Site of Privileges - LVH-M
David G. Kane, PA
Physician Extender
Physician Assistant- PA
(Orthopaedic Associates of Bethlehem, Inc- Ranjan Sachdev, MD)
Site of Privileges - LVH-M
Erika L. Keller, CNM
Physician Extender
Professional - CNM
(The Midwives & Associates Inc- Garry C. Karounos, MD)
Site of Privileges - LVH
Cynthia S. Kisner, PA·C
Physician Extender
Physician Assistant· PA-C
(Peripheral Vascular Surgeons, PC -Victor J. Celani, MD)
Site of Privileges - LVH & LVH-M
Eileen M. Klang, LPN
Physician Extender
Professional - LPN
(College Heights OBGYN Associates, PC - Thomas Hutchinson, MD)
Site of Privileges - LVH & LVH-M
Mary Ann T. Licwinko, CRNA
Physician Extender
Professional - CRNA
(Allentown Anesthesia Associates Inc- Alphonse A. Maffeo, MD)
Site of Privileges - LVH & LVH-M
Judith M. McDevitt, CRNP
Physician Extender
Professional - CRNP
(The Heart Care Group, PC- Joseph L. Neri, DO)
Site of Privileges - LVH & LVH-M
Georgiann Morgan, RN
Physician Extender
Professional - RN
(Opcor, PC- Fernando M. Garzia, MD)
Site of Privileges - LVH & LVH-M
Bradley A. Nace, PA-C
Physician Extender
Physician Assistant- PA-C
(Lehigh Valley Orthopedic Group, PC - Randy Jaeger, MD)
Site of Privileges - LVH & LVH-M
Ann Jeanette Peiffer, PA·C
Physician Extender
Physician Assistant- PA-C
(Opcor, PC- Fernando M. Garzia, MD)
Site of Privileges - LVH & LVH-M

Number2
Robert J. Peterson, PA-C
Physician Extender
Physician Assistant- PA-C
(Orthopaedic Associates of Bethlehem, Inc - Peter W. Kozicky, MD)
Site of Privileges • LVH-M

Change of Supervising Physician
Suzanne D. Amant, PA-C
Physician Extender
Physician Assistant- PA-C
From: Gastroenterology Associates Ltd • Michael H. Ufberg, MD
To: Gastroenterology Associates Ltd- J. Harry Pickle, MD
Site of Privileges • LVH & LVH-M
Dena L. Capobianco, PA-C
Physician Extender
Physician Assistant- PA-C
From: Gastroenterology Associates Ltd • Michael H. Ufberg, MD
To: Gastroenterology Associates Ltd- J. Harry Pickle, MD
Site of Privileges - LVH & LVH-M
Cynthia L. Dinsmore, CNM
Physician Extender
Professional - CNM
From: M. Bruce Viechnicki, MD & Associates PC - M. Bruce
Viechnicki, MD
To: Lehigh Valley Women's Health Care Alliance- Carolyn Scott, MD
Site of Privileges - LVH

Additional Supervising Physician
Constance A. Molchany, CRNP
Physician Extender
Professional - CRNP
Additional Supervising Physician: Robert X. Murphy, Jr., MD • Wound
Healing Program at LVH-M
Site of Privileges - LVH & LVH-M

Resignations
Lorraine 0. Dillon, PA-C
Physician Extender
Physician Assistant
(LVPG-Trauma Surgery)
Marjorie S. Hardy, PhD
Associate Scientific
Psychologist
(Muhlenberg College)
Jennifer M. Knights, PA-C
Physician Extender
Physician Assistant
(Orthopaedic Associates of Allentown)
Patricia A. Landis, CST
Physician Extender
Technical- Surgical Technician
(Orthopaedic Associates of Bethlehem Inc)

Wendy D. Grube, CRNP
Physician Extender
Professional- CRNP
From: Stephen K. Klasko, MD
To: OB-GYN at Trexlertown, PC- Larry R. Glazerman, MD
Site of Privileges - LVH & LVH-M

Chantal M. Lobo, CRNP
Physician Extender
Professional
(ABC Family Pediatricians)

Cheryl L. Lichner, CRNP
Physician Extender

Gabriel 0. Ozonuwe, PA-C
Physician Extender
Physician Assistant
(LVPG-Trauma Surgery)

Professional - CRNP

From: Stephen K. Klasko, MD
To: 08-GYN at Trexlertown, PC- Larry R. Glazerman, MD
Site of Privileges - LVH & LVH-M
Janice A. Walck, CRNP
Physician Extender
Professional - CRNP
From: Department of Medicine- John P. Fitzgibbons, MD
To: Valley Gastroenterologists- Richard L. London, MD
Site of Privileges - LVH & LVH-M
Karen M. Williams, CRNP
Physician Extender
Professional - CRNP
From: Department of Medicine- John P. Fitzgibbons, MD
To: Good Shepherd Physician Group- Jane Dorval, MD
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John & Dorothy Morgan Cancer Center

LEHu;HVAILEY

Gregory R. Harper, M.D.. Ph.D.
Physician in Chief, Cancer Services
Suite 408
1240 S. Cedar Crest Boulevard
Allentown. PA 18103
Phone: (610) 402-0512 Fax: (610) 402-0504
E-mail: gregory.harper@lvh.com

HOSPITAL AND
HEALTH NETWORK

January 2001

Dear Colleagues,
Lehigh Valley Hospital is committed to caring for all patients regardless of insurance coverage or
ability to pay. For 25 years, this commitment to our community for patients with cancer and
blood disorders has been through the oncology and hematology clinic, initially of the Lehigh
Valley Hospital, and since 1993, at the John and Dorothy Morgan Cancer Center.
The medical oncologists and hematologists at Lehigh Valley Hospital remain committed to
caring for patients and their families regardless of financial circumstances. Starting in February
2001, these patients will be seen in the private offices of our participating oncologists: Drs. Shah,
Giangiulio, and Cormier, and Drs. Aviles, Barron, Harper, and Post. This change will enhance
continuity of care, increase access to service, and facilitate flexibility in scheduling appointments
at the convenience of the patient.

All new patients requiring medical oncology/hematology consultation, whether inpatient or
outpatient, and who are under insured will be referred to the John and Dorothy Morgan Cancer
Center through 610-402-2273 (610-402-CARE). The request for referral will be communicated
to the participating practice; the practice office will contact the referring physician (office) to
obtain the appropriate information as they would for any referral, and the referring physician will
be requested to talk to the consulting oncologist/hematologist before the appointment is
confirmed.
Consultation requests for radiation oncology will continue to be directed to 610-402-0700-this
does not represent a change in current practice for referrals to radiation oncology.

On behalf of the oncologists and hematologists at the John and Dorothy Morgan Cancer Center,
I am pleased to announce this change, which we believe will lead to improved physician and
patient satisfaction with our cancer services.
Wishing you all the very best in the New Year.
Sincerely yours,

Gregory R. Harper, MD, Ph.D.

Physician in Chief

Publications

http://www .deadiversion. usdoj .gov/pubs/pressrelldr_scarn.htJ
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Publications > Press Releases > Physician Scam

Press Release

ALERT - PHYSICIAN SCAM - ALERT
The following has recently come to the attention of the Drug Enforcement
Administration, Office of Diversion Control:

The Medical Society of New Jersey has recently learned that con artists have targeted
physicians with a phony questionnaire asking for vital, confidential information,
including the physician's DEA numbers, social security number and credit card data.
The New Jersey State Attorney General is investigating this mailing sent to physicians
on what appears to be New Jersey Division of Consumer Affairs letterhead, which
seeks to "update" physician "profiles in our system." The letter claims that by
responding, a physician could order controlled dangerous substances over the phone
or via the internet.
Not only could the solicited personal information make the physician a victim of
financial fraud, but the confidential professional information - such as DEA numbercould facilitate illegal drug trafficking. In fact, the fraudulent questionnaire asks the
physician to provide two signature samples ... "as you sign on your prescription pad."
Do not respond if you have received such a questionnaire. The Division of Consumer
Affairs verifies that this is not their mailing, and that the return address with a Newark
post office box is for a non-government entity. Contact the Division of Consumer Affairs
at 1-800-242-5846 or the New Jersey State Board of Medical Examiners at
609-826-7100 if you have any doubts regarding the authenticity of any document
received from a state agency.
If you believe that you may have recently filled out and sent in such a questionnaire,
immediately contact the Consumer Affairs Enforcement Bureau during regular business
hours at 973-504-6300.
The Medical Society of New Jersey is assisting the Division of Consumer Affairs in
alerting physicians about this scam and will continue to update you as necessary.
Continue to check www.msnj.org for additional postings.
If you reside outside of New Jersey and have experienced a similar inquiry, please
contact your state professional board and/or consumer affairs division. Always
safeguard your personal and professional data. Always verify the need and authority of
unusual requests for information.

1 of2
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February 2001
Computer-Based Training (CBT):

News from the Library
OVID Training.
The Library has completely converted to OVID's online MEDLINE system. This Web-based system is
updated daily by Ovid. Call Barbara Iobst in the
Health Sciences Library at 610-402-8408 to schedule
a one-on-one training session.

New Publications in the CC Campus Library.
"Cultural Competence Compendium"
Author: American Medical Association
Description: This publication "includes resources for health
care and communication issues confronting people from
underrepresented and underserved racial, ethnic, and
socioeconomic groups and those with physical and mental
illnesses or disabilities."

Computer Based Training (CBT) programs are available for
LVHHN staff. Topics covered by the CBT programs include:
Access 2.0
Power-Point 4.0
Windows NT 4
Word 97
Excel 97
Access 97
PowerPoint 97
Lotus 1-2-3 Millennium
WordPerfect 8
E-mail GUI
PHAMIS LastWord Inquiry Only commands
CBT programs replace the instructor-led classes previously
held at Lehigh Valley Hospital. A proctor will be in the room
with the learner while he/she takes the CBT, but the learner
will control the pace and objectives of the learning.
Computer Based Training takes place in Suite 401 of the John
& Dorothy Morgan Cancer Center (the computer training
room) and in the Muhlenberg Hospital Center computer
training room (offthe front lobby). The schedule of
upcoming dates is as follows:
CBT sessions for JDMCC, suite 401 are as follows:

New Publications in the 17 Street Library.
"Mayo Clinic's Complete Guide for Family Physicians and
Residents in Training"
Author: R. Bratton
Description: "This guide takes a different approach aimed at
-the individual physician or resident physician and focuses on
what this person can expect and how to survive the labors of
residency training and being in family practice." It includes
information on consultation/
referrals, teaching, time management, computers, osteopathic
medicine in family practice, board certification/recertification
etc.
'

New Publications in the LVH-Muhlenberg Library.
"Pocket Atlas of Emergency Medicine"
Author: K. Knoop, et al.

March 13, 8 am- Noon
Sessions at MHC, I.S. Training room are as follows:
March 20, Noon- 4pm
Twelve slots are available for each session.
To register, please contact Suzanne Rice via e-mail or at 484884-2560 with the following:
date of session
second date choice
department
phone number
You will receive an e-mail confirming your choice within two
business days. If you have any questions, please contact Craig
Koller at 610-402-1427 or through e-mail.

Any questions, concerns or comments on articles from CEDS, please
contact Bonnie Schoeneberger 610-402-1210
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610-402-2379

Rita Bendekovits (Manager)
Arlene Adamczak

610-402-2484
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Continuing Education
Bonnie Schoeneberger

610-402-2584
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Sallie Urffer (Manager)
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610-402-2556
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610-402-2509
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Conference Room
610-402-2597

Fox Number
610-402-2203
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Center for Educational Development and Support
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PO Box 7017
Allentown, PA 18015-7017

Inner office mo1'ling address:
Center for Educational Development and Support
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1"th & Chew
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LEHU!HVAILEY
HOSPITAl,

THERAPEUTICS AT A GLANCE
The following actions were taken at the November· December 2000 Therapeutics Committee Meeting- Clinical Pharmacy Services
Joseph Ottinger, R.Ph., MS, MBA, Christopher Moore, Pharm.D., Janine Barnaby, R.Ph.
'

Herbal Anticoagulants
I have been asked to provide a list of herbal
remedies that have demonstrated antiplatelet
activity or those that can affect bleeding times.
It is important to remember that the discovery
of warfarin was related to the observation that
a group of bovines who ingested spoiled clover
silage died from internal hemorrhage.
Therefore it is not unrealistic that other plantderived medicinals could have similar effects.
Please remember that some of the data comes
from in vitro studies and case reports.
However it is important to take these factors
into consideration when treating patients who
take herbal remedies. Please consider the
acknowledgment of herbal remedies when
taking patient histories. At LVH, we treat
herbal remedies as medications.

Anticoagulant Herbal Products
Alfalfa
Angelica
Aniseed
Arnica
Asafoetida
Bogbean
Celery Seed
Cassia
Chamomile, German
Chamomile, Roman
Chondroitin
Clove
Danshen
DHEA
Donq Quai
Evening Primrose Oil
Fenugreek
Feverfew
Fucus

Garlic
Ginger
Gingko
Ginseng,Panax
Goldenseal
Horse-chestnut
Horseradish
Liquorice
Meadowsweet
Melilot
Poplar
Prickly Ash
Quassia
Red Clover
Woodruff
Tonka Beans
Willow
Yarrow

This list was modified from The Coumadin
Drug and Herbal Product Guide, Dupont
Pharma Inc. The authors of this reference
cited numerous references from peer reviewed
medical literature.

Budesonide For Pediatrics
Therapeutics Committee has approved the
addition of budesonide suspension for
inhalation to LVH formulary. This agent is a
significant addition because it represents the
only commercially available form of nebulized
corticosteroid. It is currently only indicated
for children. (12 months to 8 years of age)
Please be aware that the drug requires the use
of a jet-nublizer NOT an ultrasonic nebulizer.

Alendronate Weekly
Alendronate 70 mg tablets were added to LVH
formulary. In clinical trials, it was
demonstrated that the drug has the same
efficacy and same incidence of side effects
when administered by this method. This
addition will hopefully promote patient
compliance and decrease the risk of an adverse
drug reaction as opposed to administering
seven - 10 mg tablets once per week.

ADR Reporting
The quantity of Suspected ADR reports for the
third quarter of 2000 were significantly
reduced. The incidence ratios were the lowest
on record. Unfortunately, this was felt to be
due primarily to a decline in reports from

Page22

pharmacist-based observers. Staff pharmacists
were alerted to this trend and have responded
appropriately. Suspected incidents continue to
represent a 'normal' pattern of manifestations
consistent with the level of usage of specific
groups of agents and the volume of activity in
certain clinical areas. Only three 11 Severe 11
case reports were identified. With two of these
episodes being the primary reason for the
patient's admission to the hospital. An
increase in reporting reactions from oncology
areas continued; marking the second straight
quarter where improved reporting was noted.
This was principally perceived to be the direct
result of additional clinical pharmacist
interventions. One of the outcomes of this
reporting was the development of a
Hypersensitivity treatment Protocol to be
published in this newsletter under a separate
heading.
All health-care personnel are encouraged to
report suspected adverse drug reactions.
Copies of the Suspected Adverse Drug
Reaction Documentation Form are available in
all patient care areas. Complete as many
portions of the form as you can or at least
notify the Pharmacy staff of your observations.
A pharmacist will review the case and
complete/initiate the form as necessary. ALL
REPORTS are confidential and they are
summarized and presented to the Therapeutics
committee. Cause-effect analysis and trending
considerations are reviewed in this process.
Patient allergy data are updated in accordance
with the level of suspicion based on the
Naranjo scale and patient's may receive 11 ID 11
cards describing the nature of the reactions and
the presumed associated cause. This
information card can be carried by the patient
and presented in future health-care
interventions requiring drug treatments.

Following are the particulars for this quarter
~
2nd0tr
Reports per 10,000 doses
0.52
0. 63
Reports per 1,000 admissions 4.09
5.53

1st Otr
0.62
5.54

Third Quarter Data
Table 1: Adverse Reactions By Reporter

% ReilQrts
52.1
37.0
8.7
2.2
100

Reoorter
tf.. Re!lOrts
Pharmacist
24
17
Nurse
X-Ray Technician
4
_ _1
Physician
TOTAL
46

Table 2: Adverse Reactions By Drug Category
Drug Categorv
Antibiotics
Contrast Dyes
Psych/Neurologic Agents
Narcotic Analgesics
Anticoagulants
Dopamine
Cardiac
Oncology
Other
TOTAL

%Re!lorts

tf.. Re!lorts
14
9
7
1
7
0
0
4

30.4
19.6
15.2
2.2
15.2

0
0
8.7
8.7
100

1
46

Table 3: Probability of Drug-Related Reactions

% Re!lorts

Probability
tf.. Re!lorts
Doubtful
0
Possible
12
Probable
31
Highly Probable _3
TOTAL
46

0
26.1
67.4

M
100

Table 4: Adverse Reaction Severity
Classification
Mild
Moderate
Severe
TOTAL

!!.. Re!lorts
17
26
_3
46

~

Re!lorts Most Common
37.0
Contrast dye- 6
56.5 abcix w/hep;inflix-3
6.5
see case
100
reports- 1 each
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Drug Formulary IssuesArgatroban
Argatroban is indicated for use as an
anticoagulant for prophylaxis or treatment of
thrombosis in patients with heparin-induced
thrombocytopenia (HIT). Argatroban may also
have potential utility in disseminated
intravascular coagulation (DIC), as an adjunct to
thrombolytic agents in the treatment of acute
myocardial infarction, heparin-induced
thrombosis syndrome, and stroke. Other agents
used in patients with heparin-induced
thrombocytopenia are danaparoid and lepirudin.
The FDA-approved indications for argatroban and
lepirudin are summarized in Table 1.
Table 1: FDA-Approved Indications for
Argatroban and Lepirudin:
Indication
Anticoagulation for
prophylaxis of
thrombosis in
patients with HIT
Anticoagulation for
treatment of
thromboembolic
disease (to prevent
further
complications) in
patients with HIT

Argatroban

Lepirudin

X

X

Acute HIT is managed by the discontinuation of
the heparin therapy. Warfarin is not used as a
substitute for the heparin during acute HIT
because it can deplete protein C and cause
microvascular thrombosis. Warfarin therapy
should be delayed until the platelet count has
returned to normal levels. Low molecular weight
heparins are also not universal substitutes for
heparin in a patient with acute HIT because
platelet aggregation cross-reactivity in vitro has
been demonstrated with some of these products.
Danaparoid, a heparinoid, may be useful in some
patients.
Danaparoid has a lower risk of
nonidiosyncratic platelet activation and less crossreactivity for HIT-IgG than unfractionated heparin
and the other low molecular weight heparins.
Hirudin, a recombinant antithrombin similar to
that found in the salivary gland of a medicinal
leech, is another potential alternative agent.
Argatroban and lepirudin are approved for use as
an anticoagulant for the treatment of
thromboembolic disease in patients with HIT and
argatroban is approved for the prophylaxis of
thrombosis in patients with HIT.

X

HIT occurs in 1% to 5% of the patients treated
with unfractionated heparin. Generally, HIT
develops after 5 to 8 days of heparin therapy, but
it may occur earlier in patients who have received
heparin therapy during the previous 3 months. It
can result in numerous thrombotic complications,
such as stroke, myocardial infarction, deep venous
thrombosis, pulmonary embolism, and ischemic
damage of a limb. The risk of developing HIT is
higher with porcine heparin than beef heparin,
unfractionated heparin than low-molecular-weight
heparin, and patients treated with high-dose
heparin versus low-dose heparin.

CLINICAL PHARMACOLOGY: Argatroban
is a synthetic, reversible direct thrombin inhibitor.
Argatroban is highly selective for thrombin. At
therapeutic concentrations, it has little or no effect
on related serine proteases (trypsin, factor Xa,
plasmin, and kallikrein). It can inhibit the action
of both free and clot-associated thrombin.
Argatroban also inhibits the form~tion of
thrombin-antithrombin III (ATill) complexes by
competing with A Till for thrombin. By inhibiting
the catalytic site of thrombin, argatroban
subsequently affects the conversion of fibrinogen
to fibrin, the formation of the thrombinantithrombin III complex, platelet aggregation, the
release ofplasminogen activator from vessel walls
and activation of factors V, VIII, and XIII.
Argatroban does not accelerate the consumption
of ATill, in contrast to heparin, but rather is
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consumed in lieu of ATill and is thus potentially
useful in ATill-deficient situations. In addition,
it appears to reduce the vasomotor effects of
thrombin.
This is significant in the treatment of certain
pathologies.
For example, ATill-deficient
patients see a greater occurrence of thrombosis
and ATill is decreased in disseminated
intravascular coagulation (DIC). Heparin is
dependent on ATIII for its activity while
argatroban works independently of the blood
component. Argatroban is not neutralized like
heparin by platelet products (factor IV) and is
more effective against clot-bound thrombin than
hirudin. Clot-bound thrombin is resistant to the
inhibitory effects of the heparin-ATIII complex.
In contrast, argatroban inhibits clot-bound as well
as free thrombin.

Table 2: Comparison of Selected
Anticoagulants:

Argatroban

Heparin

Hirudin

Lepirudln

526.66

12,000

7,000

6979.5

Direct Thrombin Inhibition

Yes

No

Yes

Yes

Inhibition Speed

Fast

Fast

Slow

Slow

++

+++

+++

Reversible

Reversible

Irreversible

Irreversible

Effect on a.P1T

++

+++

+++

+++

Effect on PT

++

+

+++

+++

Effect on TI

++

+++

+++

+++

Inhibition of Clot-Bound
Thrombin

+++

0

+

+

Antithrombotic Efficacy

+++

++

+++

+++

Hemorrhagic Potential

++

+++

+++

+++

0

0

0

0

Molecular Weight (D)

Thrombin Binding Affinity
Reversibility

Inhibition ofThrombolysis

When administered by continuous infusion,
anticoagulant effects and plasma concentrations
follow similar, predictable temporal response
profiles, with low intersubject variability.
Immediately upon initiation of infusion,
anticoagulant effects are produced as plasma
argatroban levels begin to rise. Steady-state levels
ofboth drug and anticoagulant effect are typically
attained within 1 to 3 hours and are maintained
until the infusion is discontinued or the dosage
adjusted. Dissipation of the anticoagulant effects
was about 4-fold faster for argatroban than
heparin. Argatroban' s reversible inhibition, in
comparison to hirudin's essentially irreversible
inhibition, may represent a distinct advantage.
Rapid dissociation of argatroban from thrombin
would be expected to lead to a more rapid return
of aPTT and ACT to normal values (see Table 2).
However, this reversibility may also be associated
with a greater propensity for induction of a
hypercoagulable state after administration is
terminated.

+

I

Argatroban does not interact with heparininduced antibodies. Antibody formation to
argatroban has not been observed.
PHARMACOKINETICS: Argatroban binds
rapidly to thrombin at the catalytic site and
apolar region at a diffusion controlled rate.
Since antithrombotic efficacy of thrombin
inhibitors requires rapid complete inhibition of
local thrombin concentrations, a more rapid
association rate (as argatroban possesses versus
hirudin) may translate into a clinical advantage.

The mean half-life of argatroban is about 40
minutes. Argatroban is primarily metabolized
by hydroxylation and aromatization in the liver
to four known metabolites. Cytochrome P450
3A4/5 enzyme has been identified to catalyze
formation of the metabolites in vitro, although it
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does not appear to play a significant role in the
in vivo metabolism of argatroban.
The pharmacokinetics of argatroban were not
altered in subjects with mild, moderate, or
severe renal impairment. Renal impairment
appears to only mildly influence aPTT and ACT
values achieved while receiving argatroban.
Dosage adjustments are recommended in
patients with hepatic impairment.

In patients with hepatic impairment, therapy
should be initiated at a lower dose and carefully
titrated. Upon discontinuation of therapy, full
reversal of anticoagulant effects may require
longer than 4 hours due to decreased clearance.
The safety and effectiveness of argatroban have
not been established in patients under 18 years of
age.
Argatroban is in Pregt?.ancy Category B.

COMPARATIVEEFFICACY: FDA
approval was granted on the bases of a
historically controlled efficacy and safety study
and a follow-on efficacy and safety study.
CONTRAINDICATIONS, WARNINGS, AND
PRECAUTIONS: Argatroban is contraindicated
in patients with overt major bleeding, and in
patients hypersensitive to argatroban or an of the
product ingredients (D-sorbitol, dehydrated
alcohol)'
Individuals with a condition
predisposing them to a bleed should also be
assessed for the benefit oftherapy with argatroban
and be closely monitored. Examples of conditions
that might put a person at risk ofbleeding include
duodenal and gastric ulcers, history of a recent
operative or invasive procedure, renal
insufficiency, sub-acute bacterial endocarditis, or
thrombocytopenia.
Argatroban should be used with extreme caution
in disease states and other circumstances in which
there is an increased risk of hemorrhage,
When argatro ban therapy needs to be
discontinued, some sources have recommended
tapering the dose instead ofabruptly discontinuing
the drug. Abrupt discontinuation may lead to a
hypercoagulable state since some patients have
shown an increase in concentration of thrombinantithrombin III complex within 2 hours of
discontinuation of the argatroban infusion.

ADVERSE EFFECTS: The side effects reported
with argatroban include hypotension, fever,
diarrhea, ventricular tachycardia, vomiting,
bleeding, hemorrhage, dizziness, headache,
injection site reactions, nausea, pain, rash, and
rebound anginal symptoms. In addition, increases
in serum transaminases have been reported.
Table 3: Adverse Events in the Historically
Controlled Trials of Argatroban:

Events

Major H~morrhaglc EwntJ
Gastrointestinal
Genitourinary and hematuria
Decrease hemoglobin/hematocrit
Multisystem hemoiThage and DIC
Limb and BKA stump
Intracranial hemoiThage
Minor H-rrhaglc EventJ
Gastrointestinal
Genitourinary and hematuria

Decrease hemoglobin/hematocrit
Groin
HemoptySis
Brachial
Non-h-rrhaglc Events
Dyspnea
Hypotension
Fevet
DiiiiThea
Sepsis
Cardiac mest
Nausea
Ventricular tachycardia
Pain
Urinary tract infection
Vomiting
Infection
Pneumonia
Atrial fibrillation
Coughing
Abnormal renal function
Abdominal pain
Cetebrovascuiat disorder

Argatroban
(n-568)

Controlll

2.3%
0.9%
0.7%

1.6%
0.5%
0%
I%
0%

0.5%
0.5%
O"AI
14.4%
11.6%
10.4%

5.4%
2.9%
2.4%
8.1%
7.2%
6.9%
6.2%
6%

5.8%
4.8%
4.8%
4.6%
4.6%
4.2%
3.7%
3.3%
3%
2.8%
2.8%
2.6%
2.3%

(n•193)

O.S%
18.1%
0.8%
0%
3.1%
0.8%
0.8%
8.8%
2.6%
2.1%
1.6%
12.4%
3.1%
0.5%
3.1%
3.1%
5.2%
0%
3.6%
9.3%
11.4%
1.6%
4.7%
1.6%
4.1%

Page26

Allergic reactions were reported in 156 patients
receiving argatrob~n in other studies.
Approximately 95% ofthese reactions occurred in
patients receiving concomitant streptokinase
and/or contrast media.

DRUG INTERACTIONS: Concomitant use of
argatroban with antiplatelet agents, thrombolytics,
and other anticoagulants may increase the risk of
bleeding.
Pharmacokinetic interactions between argatroban
and warfarin have not been observed; however,
concomitant administration does result in
prolongation of the PT and INR (see Monitoring).
The combination of argatroban and warfarin does
not result in further reduction in vitamin K
dependent factor Xa activity than that which is
seen with warfarin alone.

MONITORING: The aPTT values must be
monitored in all patients. Anticoagulation effects
associated with argatroban at doses up to 40
meg/kg/min are well correlated with the aPTT.
The aPTT and ACT are both effective for
monitoring argatroban therapy. The aPTT can be
used monitor argatroban at levels of 0.04 to 2.5
mcg/mL. The ACT can be used to monitor higher
levels of argatroban (1 to 15 mcg/mL) achieved
during revascularization procedures.
The aPTT should be monitored daily as well as 2
hours after the start of infusion and 2 hours after
each dosage adjustment. The aPTT should be
kept within 1.5 to 3 times control. Current
laboratory 'normal' aPTT is 20.6-37.7 seconds.
Prothrombin time or INR cannot always be
reliably used to monitor warfarin while patients
on argatroban are being converted to oral
anticoagulant therapy, as argatroban
synergistically interferes with the INR. The
relationship between INR on co-therapy and
warfarin alone is dependent on the dose of
argatroban and the thromboplastin reagent used.

INR should be measured daily while argatroban
and warfarin are coadministered. In general, with
argatroban doses up to 2 meg/kg/min, argatroban
can be discontinued when the INR is greater than
4 on combined therapy. After argatroban is
discontinued, the INR should be measured in 4 to
6 hours. If the repeat INR is below the desired
range, argatroban therapy should be resumed and
the procedure repeated daily until the desired
therapeutic range with warfarin is achieved. For
argatroban doses greater than 2 meg/kg/min, the
dose should be temporarily reduced to a dose of2
meg/kg/min and the INR measured 4 to 6 hours
later.
No antidote/antagonist presently exists for
argatroban; however, its relatively rapid clearance
from the plasma nearly eliminates a need for such
an agent. At therapeutic levels, anticoagulation
parameters usually return to normal within 2 to 4
hours after discontinuation of argatroban,
although reversal may take longer in patients with
hepatic impairment.

DOSING: Prior to initiating therapy, heparin
therapy should be discontinued and a baseline
aPTT obtained. The recommended initial dose for
adult patients with IDT, and without hepatic
impairment, is 2 meg/kg/min, administered as a
continuous infusion. The aPTT should be
checked 2 hours after initiation of therapy to
confirm the aPTT is within the desired range, and
dosage adjustments made as necessary. The dose
can be adjusted as clinically indicated, but not to
exceed 10 meg/kg/min, until the steady-state
aPTT is 1.5 to 3 times the initial baseline (not to
exceed 100 seconds).
For patients with moderate hepatic impairment, an
initial dose of 0.5 meg/kg/min is recommended,
based on the approximately 4-fold decrease in
argatroban clearance compared to patients with
normal hepatic function. The aPTT should be
monitored closely and the dosage adjusted as
needed.
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Some sources have recommended argatroban
therapy be tapered rather than abruptly halted
when it needs to be discontinued.
CONCLUSION: Argatroban appears to be a
useful agent in the treatment of patients with
heparin-induced thrombocytopenia, although
comparative data with lepirudin and danaparoid
are lacking. Its usefulness in the treatment of
other conditions will require documentation from
controlled clinical trials and will be dependent on
the drug's cost and safety. Argatroban may offer
a safety advantage over lepirudin, in that it is
shorter acting and rapidly eliminated even in
patients with renal impairment. In addition, it
appears to inhibit thrombin faster; inhibits clotbound thrombin to a more significant degree than
lepirudin. The cost of a single therapy day for an
80 kg patient with normal renal/hepatic function
is estimated to be $875 per day (lepirudin) vs
$600 per day (argatroban). Argatroban would
appear to be an agent that should be added to the
LVH Drug formulary for selected use in those
patients needing parenteral anticoagulation where
heparin products may be deleterious. The
Therapeutics Committee recommended that it
replace lepirudan given the current information.

Lamisil Rejected
Terbinafine (Lamisil®) cream was not approved
to be added to LVH formulary. Instead, an
autosub with clotrimazole (Lotrimin®) will be
instituted. In studies comparing the two agents,
both were equally efficacious against tinea pedis,
cruris and corporis due to E.floccosum, T.
mentagrophytes or T .rubum, Clotrimazole also
showed greater activity against Candida. The dose
of clotrimazole will be 1 application twice daily.

Hypersensitivity Protocol
Therapeutics committee approved a
hypersensitivity protocol for use throughout the
hospital.
The protocol originated in the
hematology/oncology division for use in these
patients and a checkbox was added to the
antineoplastic order sheet. The rationale is that the
nurses can start to administer medication
(specifically diphenhydramine) to the patient
while waiting for the physician to call back with
further orders.
The protocol is as follows:
1.
Stop infusion
page physician
immediately
2.
NSS IOOmllhr
3.
Monitor BP, pulse, Sa02
4.
Give diphenhydramine 50mg IV and have
epinephrine 1:1000 available
5.
2Limin 0 2 as needed
A check box is being added to all physician order
sheets which will be located aside of the check off
box stating no allergies. By checking the box, the
hypersensitivity protocol will be enacted in case
of a hypersensitivity reaction.

Heparin Order sheet
A revised intravenous heparin order sheet has
been developed to facilitate use of this important
agent. The order sheet will contain the more
widely used dosing schemes, but physicians will
be able to describe individually tailored regimens
for those patients that would benefit from such
alterations. The order format incorporates the
new therapeutic ranges identified in the LAB
LINK. A copy of the two sided form is attached
to this newsletter.
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HEPARIN ORDER SHEET
DRUG INTOLERANCES:

DRUG ALLERGIES:

REACTIONS:

REACTIONS:

NONE KNOWN
telected Protocols for Treatment and heparin dose
djustments are listed on the reverse side of this
form
If the patient _lli ~candidate for Low Molecular Weight heparin for the treatment of uncomplicated DVT with Q! without!%.
enoxaparin lmglkg g 12h ~ or
g24h ~ has been shown to be as equally efficacious and safe as unfractionated heparin.
Please initiate the "Ou:toatient" DVT treatment protocol and use that order set.
Current laboratory standards for aPTT are listed below:
Height=
Normal= 21-38 seconds
Equivalent therapeutic aPTT range for 0.3- 0.7 units/ml heparin level (based on anti-factor Xa
activity)= 68-113 seconds
Weight (kg)=

u mm

1.:. Identify reason for use (CHECK ONE): Unstable angina/MI

Treatment of DVT/PE
Stroke
Other
SELECT TREATMENT REGIMEN (CHECK ONE)
Use "Cardiac" dosing protocol (ACC/AHA Modei)-See reverse side gforder.
£:
Use Modified Raschke dosing protocol <PEIDVD-See reverse side gf order.
Use StrokeffiA dosing protocol. See reverse side gf order.
Use specific dosing regimen identified below (Must describe heparin dose modifications and PTT targets
on this order sheet below)
.1. Obtain baseline • aPTT, CBC prior to initiating therapy. if not already done in previous 24 hr
period. If baseline aPTT elevated, call physician to notifv.
4. Obtain patient weight in kg, prior to initiating theraov. Complete weight field
~ Obtain aPTT ~ hours after each dosing adJustment until targeted aPTT range is achieved. Modify dose as
directed ~ preselected protocol or as directed below. Once targeted aPTT range is achieved. obtain aPTT
dai~ to monitor.
6. Obtain platelet count every
~ Call if platelet count <100,000/mm 3
1. 1f heparin dose i.§. greater than 20 units/kg hr without attaining 9. targeted aPTT. obtain HEPARIN LEVEL
Yes
No
8. Test all stools for occult blood
9 Make all dosing adjustments as

prompt!~

as possible as directed. Round all doses to the nearest 100 units.

Dosing scale must be completed below, if none ofthe formatted protocols is selected above
Initial heparin bolus:

units now.
Immediately follow with infusion ofheparin 25,000 units/ 250 mls (100 units/ml) and adjust the infusion rate as
follows: (Only Complete if you checked off 'specific dosing protocol
PTT value (s) (SECONDS)

IFPTI
IFPTI
IFPTI
IFPTI
IFPPT
IFPTI
IFPTI

Heparin adjustment (s)
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Loading dose of 60 units/kg (maximum bolus 4.000 units). followed J2y an initial infusion rate of 12
unitslkglhr (maximum 1.000 units/hr. Adjust as indicated below.

ACC/AHA <Cardiac Protocol)

Cardiac heparin protocol adjustments
PTI <38
Give 40 unit/kg bolus (maximum 4,000 units):increase heparin infusion rate by
I 00 unitslhr (<80kg) OR
200 unitslhr (~80kg)
PTI 38-55

Give 20 unit/kg bolus; increase heparin infusion rate by
100 unitslhr (all weights)

PTI 56-67

Increase heparin infusion by
100 unitslhr (all weights)

PTI 68-95

NO CHANGE

PTI 96-125

Decrease heparin infusion rate by
I 00 units/hr (all weights)

PTI 126-160

Decrease heparin infusion rate by
I 00 unitslhr (<80kg) OR
200 units/hr (~80kg)

PTI 161-200

Stop heparin for I hour. Decrease heparin infusion rate by
200 units/hr (<80kg)
300 unitslhr (~80kg)

PTI> 200
CALL PHYSICIAN FOR FURTilER ORDERS
Raschke (DVT/PE protocol) Loading dose of 80 units/kg, followed by m initial infusion rate of 18 units/kg/hr. Target PTT 1.5-2.5
times PTT control. Adjust M indicated below.
Modified Raschke heparin protocol adjustments <PEIDVT)
PTI < 38

80 unit/kg bolus. Increase infusion rate by
4 units/kglhr

PTI 38-67

40 units/kg bolus. Increase infusion rate by
2 units/kglhr

PTI 68-ll3

NO CHANGE

PTT 114-140

Reduce infusion rate by I unitslkglhr

PTT 141-170

Reduce infusion rate by 2 units/kglhr

PTT 171-210

Hold heparin for one hour. Reduce infusion rate by 3 units/kg/hr.

P~21 0

CALL PHYSICIAN FOR FUR1HER ORDERS.

Stroke/TIA protocol Loading dose not recommended. Initiate infusion rate at 15 units/kg/hr. Adjust as Indicated
below
Strokefl'IA heparin protocol adjustments
PTI <55
Increase infusion rate by 100 units/hr
PTT 55-ll3

NO CHANGE

PIT 114-150

Decrease infusion rate by 100 unitslhr

PTI> 150

Hold he arin for 2 hours. Reduce infusion rate b 200 units/hr

LEHI01VAILEY

Non-Profit Org.
U.S. Postage
PAID
Allentown, PA
Permit No. 1922

HOSPITAL AND
HF-ALTH NF.1WORK

Cedar Crest & 1-78
P.O. Box 689
Allentown, PA 18105-1556

Medical Staff Progress Notes

Medical Executive Committee

Edward M. Mullin, Jr., MD
President, Medical Staff
Alexander D. Rae-Grant, MD
President-elect Medical Staff
David M. Caccese, MD
Past President, Medical Staff
John W. Hart
Vice President
Rita M. Mest
Director, Medical Staff Services

Linda K. Blose, MD
Karen A. Bretz, MD
David M. Caccese, MD
Luis Constantin, MD
William B. Dupree, MD
Domenico Faloone, MD
John P. Fitzgibbons, MD
Herbert C. Hoover, Jr., MD
Michael W. Kaufmann, MD
Mark A. Kender, MD
Robert Kricun, MD
RobertJ. Laskowski. MD
Richard L. London, MD
Vincent R. Lucente, MD
Alphonse A. Maffeo, MD
John A. Mannisi, MD
John W. Margraf, MD
EricJ. Marsh, DMD
Stephen C. Matchett, MD
James L. McCullough, MD
William L. Miller, MD
Edward M. Mullin, Jr., MD
Brian P. Murphy, MD
John D. Nuschke, MD
Alexander D. Rae-Grant, MD
Victor R. Risch, MD
Alexander M. Rosenau, DO
Michael Scarlata, MD
Elliot I. Shoemaker, MD
Elliot J. Sussman, MD
Hugo N. Twaddle, MD
John D. VanBrakle, MD
Michael S. Weinstock, MD

Janet M. Seifert
Physician Relations
Managing Editor

Medical Staff Progress Notes
Is published monthly to
inform the Medical Staff of
Lehigh Valley Hospital and
employees of important
Issues concerning the
Medical Staff.
Articles should be submitted
to Janet M. Seifert, Physician
Relations, Lehigh Valley
Hospital, Cedar Crest & 1·78,
P.O. Box 689, Allentown, PA
18105-1556, by the 15th of
each month. If you have any
questions about the
newsletter, please call Mrs.
Seifert at (61 0) 402·8590.

